In recent years, whole-body diffusion weighted magnetic resonance imaging[13,14] and 68Ga prostate-specific membrane antigen (68Ga-PSMA) PET/CT[15,16] have emerged as a new imaging modality for monitoring the response of bone metastases to treatment in patients with prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.